Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.45 |
| ▸ | LTA4H | P09960 | 7/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | BMX | P51813 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286634 | 0.87 | S1PR1 (0.43) | S1PR1S1PR3LTA4HSPHK1SPHK2 | |
| SCHEMBL29307826 | 0.86 | SPHK1 (0.47) | S1PR1S1PR3LTA4HSPHK1SPHK2 | |
| SCHEMBL18921010 | 0.86 | SPHK1 (0.47) | S1PR1S1PR3LTA4HSPHK1SPHK2 | |
| SCHEMBL18921008 | 0.86 | SPHK1 (0.47) | S1PR1S1PR3LTA4HSPHK1SPHK2 | |
| SCHEMBL6287916 | 0.80 | CA1 (0.48) | LTA4HSPHK1 | |
| SCHEMBL6287020 | 0.80 | CA1 (0.48) | LTA4HSPHK1 | |
| SCHEMBL6286723 | 0.79 | LTA4H (0.47) | S1PR1S1PR3LTA4HSPHK1SPHK2 | |
| SCHEMBL7136775 | 0.78 | HPGD (0.46) | S1PR1S1PR3LTA4HAAK1 | |
| SCHEMBL7740801 | 0.77 | SLC1A1 (0.36) | S1PR1S1PR3LTA4HHDAC8 | |
| SCHEMBL10078349 | 0.77 | SLC1A1 (0.36) | S1PR1S1PR3LTA4HHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | S1PR1 1281/4885S1PR3 1632/4885LTA4H 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.